Sangamo Therapeutics
Sangamo Therapeutics, Inc.: A US-based biotech firm specializing in genomic therapies for genetic diseases.
Sangamo Therapeutics, Inc.: A US-based biotech firm specializing in genomic therapies for genetic diseases.
Founded in the United States, Sangamo Therapeutics, Inc. is a biotechnology company dedicated to pioneering the future of genomic medicine. The company's core mission is to translate groundbreaking science into cures for severe genetic diseases, leveraging its proprietary zinc finger technology. Sangamo focuses on developing genomic therapies that aim to provide lasting solutions rather than merely managing symptoms, addressing unmet medical needs in the field of genetic disorders.
Notable figures associated with Sangamo include its team of leading scientists and researchers who drive its innovative projects. The company has attracted significant investment from various healthcare and biotech investors, bolstering its research and development efforts. Key achievements include advancements in zinc finger technology and the development of potential treatments for conditions such as hemophilia and sickle cell disease. Sangamo's work has had a substantial impact on the biotechnology landscape, pushing the boundaries of genomic medicine and offering hope to patients with previously untreatable genetic diseases.
Companies similar to Sangamo Therapeutics include Cogent Biosciences, Encoded Therapeutics, BridgeBio Pharma and Denali Therapeutics.
Sangamo Therapeutics was founded in 1995.
Sangamo Therapeutics' headquarters is located in Richmond, CA, US.
Sangamo Therapeutics' most recent funding round was for $145.5M (USD) in April 2019.
As of Apr 3, 2019, Sangamo Therapeutics has raised a total of $522.1M (USD).
Sangamo Therapeutics has 478 employees as of Feb 5, 2024.
BridgeBio Pharma
bridgebio.com
